hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 10:04:39 - browse：5779

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： ALS advocates say criticism of new drugs misses bigger picture

focus

WSS

Medical device trials still don't enroll enough women, study finds

Advances in CAR

Crinetics acromegaly drug succeeds in late

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Statins may not be needed by millions of people, study suggests

NIH tests clinical research in primary care with $30 million program

knowledge

hotspot

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

5 takeaways from STAT's examination of Zynex Medical

DIEP, the 'gold standard' of breast reconstruction, is under threat

The (many) problems with a new study criticizing cancer screening

23andMe had bad news about my health. I wish a person had delivered it

AstraZeneca chief proposes a novel edit to the drug pricing bill

Jerome Adams on the need for new antivirals for Covid

Curing rare childhood diseases will falter unless Congress steps up

Bright Health sells Medicare Advantage business to Molina

STAT Virtual Event: ASCO Recap, Live!

hotspot

Study: Why relieving medical debt did not improve financial outcomes

NIH nominee Bertagnolli will get October confirmation hearing

Curing rare childhood diseases will falter unless Congress steps up

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

NIH tests clinical research in primary care with $30 million program

Statins may not be needed by millions of people, study suggests

Wikipedia

focus

hotspot

focus